Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria

Current Pharmaceutical Design

Volumn 17, Issue 23, 2011, Pages 2421-2427

  Griguer, Corinne E ^a   Oliva, Claudia R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Chemoresistance; Electron transport chain; Glucose metabolism; Glycolysis; Mdr; Mitochondria; Oxidative phosphorylation; Temozolomide

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; BLEOMYCIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME C OXIDASE; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; INTERFERON; LUNG RESISTANCE PROTEIN; MITOCHONDRIAL DNA; MULTIDRUG RESISTANCE PROTEIN; NITROSOUREA DERIVATIVE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

APOPTOSIS; BRAIN CANCER; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER STEM CELL; CANCER THERAPY; CELL DEATH; CELL ENERGY; DOWN REGULATION; DRUG CYTOTOXICITY; ENERGY METABOLISM; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; GLYCOLYSIS; HUMAN; INTERFEROMETER; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MULTIDRUG RESISTANCE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA, MITOCHONDRIAL; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GLIOBLASTOMA; GLUCOSE; HUMANS; MITOCHONDRIA; P-GLYCOPROTEINS; REACTIVE OXYGEN SPECIES;

EID: 80053487181     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797249251     Document Type: Review

References (75)

1. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004; 10(11): 3728-36.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
3. [Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res; 70(17): 6870-9.
4. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008; 13: 5138-54.
5. Dinca EB, Sarkaria JN, Schroeder MA, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. J Neurosurg 2007; 107(3): 610-6.
6. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol 2009; 92(1): 23-31.
7. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 2009; 11(3): 281-91.
8. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10(15): 4933-8.
9. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124(3215): 269-70.
10. Hockenbery DM. A mitochondrial Achilles' heel in cancer? Cancer Cell 2002; 2(1): 1-2.
11. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
12. Rempel A, Mathupala SP, Griffin CA, Hawkins AL, Pedersen PL. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res 1996; 56(11): 2468-71.
13. Beckner ME, Gobbel GT, Abounader R, et al. Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest 2005; 85(12): 1457-70.
14. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64(11): 3892-9.
15. Griguer CE, Oliva CR, Gillespie GY. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J Neurooncol 2005; 74(2): 123-33.
16. Racker E. History of the Pasteur effect and its pathobiology. Mol Cell Biochem 1974; 5(1-2): 17-23.
17. Warburg O. On the origin of cancer cells. Science 1956; 123(3191): 309-14.
18. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol 1927; 8(6): 519-30.
19. Muller M, Siems W, Buttgereit F, Dumdey R, Rapoport SM. Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells. Eur J Biochem 1986; 161(3): 701-5.
20. Griguer CE, Oliva CR, Gillespie GY, Gobin E, Marcorelles P, Yancey Gillespie G. Pharmacologic manipulations of mitochondrial membrane potential (DeltaPsim) selectively in glioma cells. J Neurooncol 2007; 81(1): 9-20.
21. Turcotte ML, Parliament M, Franko A, Allalunis-Turner J. Variation in mitochondrial function in hypoxia-sensitive and hypoxiatolerant human glioma cells. Br J Cancer 2002; 86(4): 619-24.
22. Bouzier AK, Goodwin R, de Gannes FM, et al. Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13c and 1H NMR study. J Biol Chem 1998; 273(42): 27162-9.
23. Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M. Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Dev Neurosci 1998; 20(4-5): 331-8.
24. Griguer C, Oliva CR, Benos, DJ, Lancaster, JR, Jr. and Gillespie, GY. Loss of Mitochondrial Function in Human Glioma Support Aggressive Tumor Phenotype Submitted 2008.
25. Chan DC. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006; 125(7): 1241-52.
26. Wiesner RJ, Ruegg JC, Morano I. Counting target molecules by exponential polymerase chain reaction: copy number of mitochondrial DNA in rat tissues. Biochem Biophys Res Commun 1992; 183(2): 553-9.
27. Kirches E, Krause G, Warich-Kirches M, et al. High frequency of mitochondrial DNA mutations in glioblastoma multiforme identified by direct sequence comparison to blood samples. Int J Cancer 2001; 93(4): 534-8.
28. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer 2002; 1: 9.
29. Yeh JJ, Lunetta KL, van Orsouw NJ, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene 2000; 19(16): 2060-6.
30. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287(5460): 2017-9.
31. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 1998; 20(3): 291-3.
32. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr Mol Med 2007; 7(1): 121-31.
33. DeHaan C, Habibi-Nazhad B, Yan E, Salloum N, Parliament M, Allalunis-Turner J. Mutation in mitochondrial complex I ND6 subunit is associated with defective response to hypoxia in human glioma cells. Mol Cancer 2004; 3: 19.
34. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6(7): 2585-97.
35. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20(9): 2388-99.
36. Gonzaga PE, Potter PM, Niu TQ, et al. Identification of the crosslink between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA. Cancer Res 1992; 52(21): 6052-8.
37. [Griguer CE, Oliva CR, Gobin E, et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 2008; 3(11): e3655.
38. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246(4929): 500-3.
39. Park SY, Chang I, Kim JY, et al. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem 2004; 279(9): 7512-20.
40. Singh KK, Russell J, Sigala B, Zhang Y, Williams J, Keshav KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999; 18(48): 6641-6.
41. [Hara K, Kasahara E, Takahashi N, et al. Mitochondria determine the efficacy of anti-cancer agents that interact with DNA but not the cytoskeleton. J Pharmacol Exp Ther 2011: In Press.
42. Biswas G, Anandatheerthavarada HK, Avadhani NG. Mechanism of mitochondrial stress-induced resistance to apoptosis in mitochondrial DNA-depleted C2C12 myocytes. Cell Death Differ 2005; 12(3): 266-78.
43. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltagedependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12(19): 5817-25.
44. Lee W, Choi HI, Kim MJ, Park SY. Depletion of mitochondrial DNA up-regulates the expression of MDR1 gene via an increase in mRNA stability. Exp Mol Med 2008; 40(1): 109-17.
45. [Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev; 3(1): 23-34.
46. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3(4): 294-300.
47. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999; 4(5): 304-29.
48. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007; 96(9): 2181-96.
49. Carmody RJ, Cotter TG. Signalling apoptosis: a radical approach. Redox Rep 2001; 6(2): 77-90.
50. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 2000; 55(1): 29-35.
51. Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J Biol Chem 2000; 275(10): 7087-94.
52. Kim JY, Kim YH, Chang I, et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene 2002; 21(20): 3139-48.
53. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006; 27(5): 925-35.
54. Grandjean F, Bremaud L, Robert J, Ratinaud MH. Alterations in the expression of cytochrome c oxidase subunits in doxorubicinresistant leukemia K562 cells. Biochem Pharmacol 2002; 63(5): 823-31.
55. Denis-Gay M, Petit JM, Mazat JP, Ratinaud MH. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells. Biochem Pharmacol 1998; 56(4): 451-7.
56. Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65(8): 3162-70.
57. [Oliva CR, Nozell SE, Diers A, et al. Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem; 285(51): 39759-67.
58. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 2001; 35(2): 161-204.
59. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5(4): 275-84.
60. [Chen L, Feng P, Li S, Long D, Cheng J, Lu Y, Zhou D. Effect of Hypoxia-inducible Factor-1alpha Silencing on the Sensitivity of Human Brain Glioma Cells to Doxorubicin and Etoposide. Neurochem Res 2008.
61. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54(22): 5902-10.
62. Decleves X, Fajac A, Lehmann-Che J, et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002; 98(2): 173-80.
63. Mohri M, Nitta H, Yamashita J. Expression of multidrug resistance- associated protein (MRP) in human gliomas. J Neurooncol 2000; 49(2): 105-15.
64. Aronica E, Gorter JA, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia 2005; 46(6): 849-57.
65. Berger W, Spiegl-Kreinecker S, Buchroithner J, et al. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 2001; 94(3): 377-82.
66. Filipits M, Pohl G, Stranzl T, et al. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91(5): 1508-13.
67. Tews DS, Nissen A, Kulgen C, Gaumann AK. Drug resistanceassociated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 2000; 50(3): 227-37.
68. Hamill DR, Suprenant KA. Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 1997; 190(1): 117-28.
69. Kong LB, Siva AC, Rome LH, Stewart PL. Structure of the vault, a ubiquitous celular component. Structure 1999; 7(4): 371-9.
70. Chugani DC, Rome LH, Kedersha NL. Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993; 106 (Pt 1): 23-9.
71. Slesina M, Inman EM, Rome LH, Volknandt W. Nuclear localization of the major vault protein in U373 cells. Cell Tissue Res 2005; 321(1): 97-104.
72. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53(7): 1475-9.
73. Wang XM, Xin H, Yang Z, et al. [Clinical study on treatment of advanced stage non-small cell lung cancer by guben xiaoliu capsule]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004; 24(11): 986-8.
74. Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 2006; 11: 300-12.
75. Manoli I, Alesci S, Blackman MR, Su YA, Rennert OM, Chrousos GP. Mitochondria as key components of the stress response. Trends Endocrinol Metab 2007; 18(5): 190-8.